Nemaline myopathy (NM) is a neuromuscular disorder characterized by muscle weakness and the presence of rod-shaped structures (nemaline bodies or rods) in affected muscle fibers. The typical, and most common, form of NM is characterized by the infantile onset of a slowly progressive or non-progressive weakness of facial, bulbar, and respiratory muscles and neck flexors. Initial weakness is primarily proximal, with later distal involvement. The typical form of NM has an autosomal recessive pattern of inheritance, and results from mutations in the NEB gene. The overall incidence of NM is estimated to be is 2 in 100,000 live births however a founder mutation in NEB (p.R2478_D2512del) has been identified in the Ashkenazi Jewish population. The carrier frequency for this mutation in this population is estimated to be 1 in 168. Testing for this mutation is expected to detect at least 95% of Ashkenazi Jewish carriers of NM. Carrier screening for NM may be considered for individuals of Eastern European (Ashkenazi) Jewish ancestry before or during pregnancy.
Full gene sequencing is available for reproductive partners of known mutation carriers. Prenatal diagnosis is also available. Prior to ordering prenatal testing, please contact our laboratory at 212-241-7518 to discuss.
1. Anderson SL. et al., (2004) Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene. Hum Genet. Aug115(3):185-90.
2. Pelin K. et al., (1999) Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci U S A. Mar 296(5):2305-10.
3. Sanoudou D, Beggs AH (2001) Clinical and genetic heterogeneity in nemaline myopathy?a disease of skeletal muscle thin filaments. Trends Mol Med 7:362?368.
4. Wallgren-Pettersson C (1990) Congenital nemaline myopathy: a longitudinal study. Commentationes Physico-Mathematicae 111:1?102.
5. Scott, S.A., Edelmann, L., Liu, L., Luo, M., Desnick, R.J. and Kornreich, R. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish Genetic Diseases. Hum. Mutat. 31:1-11, 2010.
Amniotic Fluid: 10 ml in conical tube
Cultured Cells: two confluent T-25 flasks
Additionally, please send:
5-10 ml paternal blood in EDTA (lavender top) in case paternal confirmation studies are necessary
Forms and Brochures
Carrier Screening Requisition and Consent [PDF]
Expanded Ashkenazi Jewish Carrier Screening Brochure [PDF]
Ashkenazi Jewish Carrier Screening Panel